BDBM50366826 DR-3355::Floxacin::Iquix::LEVOFLOXACIN::Levaquin

SMILES C[C@H]1COc2c3c(cc(c2N4CCN(CC4)C)F)C(=O)C(=CN31)C(=O)O

InChI Key InChIKey=GSDSWSVVBLHKDQ-UHFFFAOYSA-N

Data  2 KI  35 IC50  1 EC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 38 hits for monomerid = 50366826   

TargetPotassium voltage-gated channel subfamily H member 2(Human)
Takeda Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50366826(Levaquin | Iquix | Floxacin | DR-3355 | LEVOFLOXAC...)
Affinity DataIC50: 2.30E+6nMAssay Description:Binding affinity to human ERG Y652A tandem dimeric mutant expressed in HEK293 cells assessed as inhibition of tail current measured upon repolarizati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/1/2020
Entry Details Article
PubMed
LigandPNGBDBM50366826(Levaquin | Iquix | Floxacin | DR-3355 | LEVOFLOXAC...)
Affinity DataIC50: 1.00E+3nMAssay Description:Antibacterial activity against vancomycin-resistant Enterococcus faecalis ATCC 51299 after 18 hrs by broth microdilution methodMore data for this Ligand-Target Pair
In Depth
Date in BDB:
9/2/2020
Entry Details Article
PubMed
LigandPNGBDBM50366826(Levaquin | Iquix | Floxacin | DR-3355 | LEVOFLOXAC...)
Affinity DataIC50: 1.00E+3nMAssay Description:Antibacterial activity against vancomycin-sensitive Enterococcus faecalis 12-5 after 18 hrs by broth microdilution methodMore data for this Ligand-Target Pair
In Depth
Date in BDB:
9/2/2020
Entry Details Article
PubMed
LigandPNGBDBM50366826(Levaquin | Iquix | Floxacin | DR-3355 | LEVOFLOXAC...)
Affinity DataIC50: 1.28E+5nMAssay Description:Antibacterial activity against vancomycin-resistant Enterococcus faecalis 09-9 after 18 hrs by broth microdilution methodMore data for this Ligand-Target Pair
In Depth
Date in BDB:
9/2/2020
Entry Details Article
PubMed
LigandPNGBDBM50366826(Levaquin | Iquix | Floxacin | DR-3355 | LEVOFLOXAC...)
Affinity DataIC50: 1.00E+3nMAssay Description:Antibacterial activity against vancomycin-sensitive Enterococcus faecalis ATCC 29212 after 18 hrs by broth microdilution methodMore data for this Ligand-Target Pair
In Depth
Date in BDB:
9/2/2020
Entry Details Article
PubMed
TargetPotassium voltage-gated channel subfamily H member 2(Human)
Takeda Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50366826(Levaquin | Iquix | Floxacin | DR-3355 | LEVOFLOXAC...)
Affinity DataIC50: 5.00E+6nMAssay Description:Binding affinity to human ERG F656A tetrameric mutant expressed in HEK293 cells assessed as inhibition of tail current measured upon repolarization t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/1/2020
Entry Details Article
PubMed
TargetPotassium voltage-gated channel subfamily H member 2(Human)
Takeda Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50366826(Levaquin | Iquix | Floxacin | DR-3355 | LEVOFLOXAC...)
Affinity DataIC50: 5.00E+6nMAssay Description:Binding affinity to human ERG Y652A tetrameric mutant expressed in HEK293 cells assessed as inhibition of tail current measured upon repolarization t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/1/2020
Entry Details Article
PubMed
TargetPotassium voltage-gated channel subfamily H member 2(Human)
Takeda Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50366826(Levaquin | Iquix | Floxacin | DR-3355 | LEVOFLOXAC...)
Affinity DataIC50: 2.30E+6nMAssay Description:Binding affinity to human ERG F656A tandem dimeric mutant expressed in HEK293 cells assessed as inhibition of tail current measured upon repolarizati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/1/2020
Entry Details Article
PubMed
TargetPotassium voltage-gated channel subfamily H member 2(Human)
Takeda Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50366826(Levaquin | Iquix | Floxacin | DR-3355 | LEVOFLOXAC...)
Affinity DataIC50: 9.15E+5nMAssay Description:Inhibition of human ERG current by patch clamp assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
9/1/2020
Entry Details Article
PubMed
TargetPotassium voltage-gated channel subfamily H member 2(Human)
Takeda Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50366826(Levaquin | Iquix | Floxacin | DR-3355 | LEVOFLOXAC...)
Affinity DataIC50: 1.10E+6nMAssay Description:Binding affinity to wild type human ERG expressed in HEK293 cells assessed as inhibition of tail current measured upon repolarization to -40 mV by pa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/1/2020
Entry Details Article
PubMed
LigandPNGBDBM50366826(Levaquin | Iquix | Floxacin | DR-3355 | LEVOFLOXAC...)
Affinity DataIC50: 1.33E+5nMAssay Description:Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/3/2019
Entry Details Article
PubMed
TargetPotassium voltage-gated channel subfamily H member 2(Human)
Takeda Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50366826(Levaquin | Iquix | Floxacin | DR-3355 | LEVOFLOXAC...)
Affinity DataIC50: 2.10E+6nMAssay Description:Binding affinity to human ERG S624A tetrameric mutant expressed in HEK293 cells assessed as inhibition of tail current measured upon repolarization t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/1/2020
Entry Details Article
PubMed
TargetDNA gyrase subunit A(Staphylococcus aureus)
Daiichi Sankyo

Curated by ChEMBL
LigandPNGBDBM50366826(Levaquin | Iquix | Floxacin | DR-3355 | LEVOFLOXAC...)
Affinity DataIC50: 1.41E+6nMAssay Description:Inhibition of Staphylococcus aureus DNA gyrase Ser84Leu mutantMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/27/2020
Entry Details Article
PubMed
TargetDNA gyrase subunit A/B(Staphylococcus aureus)
Daiichi Sankyo

Curated by ChEMBL
LigandPNGBDBM50366826(Levaquin | Iquix | Floxacin | DR-3355 | LEVOFLOXAC...)
Affinity DataIC50: 2.60E+4nMAssay Description:Inhibition of Staphylococcus aureus wild type DNA gyraseMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/27/2020
Entry Details Article
PubMed
TargetDNA gyrase subunit A/B(Staphylococcus aureus)
Daiichi Sankyo

Curated by ChEMBL
LigandPNGBDBM50366826(Levaquin | Iquix | Floxacin | DR-3355 | LEVOFLOXAC...)
Affinity DataIC50: 2.57E+4nMAssay Description:Inhibition of Staphylococcus aureus MS5935 wild type DNA gyrase-mediated supercoiling activityMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2020
Entry Details Article
PubMed
TargetDNA gyrase subunit A/B(Staphylococcus aureus)
Daiichi Sankyo

Curated by ChEMBL
LigandPNGBDBM50366826(Levaquin | Iquix | Floxacin | DR-3355 | LEVOFLOXAC...)
Affinity DataIC50: 2.13E+6nMAssay Description:Inhibition of quinoline-resistant Staphylococcus aureus MS5935 DNA gyrase-mediated supercoiling activityMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2020
Entry Details Article
PubMed
TargetDNA gyrase subunit A/B(Staphylococcus aureus)
Daiichi Sankyo

Curated by ChEMBL
LigandPNGBDBM50366826(Levaquin | Iquix | Floxacin | DR-3355 | LEVOFLOXAC...)
Affinity DataIC50: 5.45E+5nMAssay Description:Inhibition of Staphylococcus aureus DNA gyrase S84L mutantMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details Article
PubMed
TargetDNA topoisomerase 4 subunit A/B(Staphylococcus aureus)
Sapienza University of Rome

Curated by ChEMBL
LigandPNGBDBM50366826(Levaquin | Iquix | Floxacin | DR-3355 | LEVOFLOXAC...)
Affinity DataIC50: 1.02E+4nMAssay Description:Inhibition of Staphylococcus aureus topoisomerase-4 expressed in Escherichia coli assessed as relaxation of pBR322 substrate measured after 4 hrs by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details Article
PubMed
TargetPlatelet-derived growth factor receptor alpha/beta(Mouse)
Medical School of Nanjing University

Curated by ChEMBL
LigandPNGBDBM50366826(Levaquin | Iquix | Floxacin | DR-3355 | LEVOFLOXAC...)
Affinity DataIC50: 3.20nMAssay Description:Inhibition of Escherichia coli DNA gyraseMore data for this Ligand-Target Pair
In Depth
Date in BDB:
4/21/2024
Entry Details
PubMed
TargetDNA topoisomerase 2-alpha/2-beta(Human)
Procter & Gamble Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50366826(Levaquin | Iquix | Floxacin | DR-3355 | LEVOFLOXAC...)
Affinity DataIC50: 8.85E+3nMAssay Description:Inhibitory activity against wild type gyrase in Escherichia coliMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2018
Entry Details Article
PubMed
TargetBile salt export pump(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM50366826(Levaquin | Iquix | Floxacin | DR-3355 | LEVOFLOXAC...)
Affinity DataIC50: 1.00E+6nMAssay Description:Inhibition of human BSEP expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptakeMore data for this Ligand-Target Pair
In Depth
Date in BDB:
5/8/2016
Entry Details Article
PubMed
TargetBile salt export pump(Rat)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM50366826(Levaquin | Iquix | Floxacin | DR-3355 | LEVOFLOXAC...)
Affinity DataIC50: 1.00E+6nMAssay Description:Inhibition of Sprague-Dawley rat Bsep expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate up...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/8/2016
Entry Details Article
PubMed
TargetDNA gyrase subunit A/B(Escherichia coli (strain K12))
Wakunaga Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50366826(Levaquin | Iquix | Floxacin | DR-3355 | LEVOFLOXAC...)
Affinity DataIC50: 470nMAssay Description:Inhibition of Escherichia coli DNA gyrase preincubated for 5 mins at 37 degC before addition of relaxed pBR322 as substrate by supercoiling assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2016
Entry Details Article
PubMed
TargetPotassium voltage-gated channel subfamily H member 2(Human)
Takeda Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50366826(Levaquin | Iquix | Floxacin | DR-3355 | LEVOFLOXAC...)
Affinity DataIC50: 9.12E+5nMAssay Description:Inhibition of human Potassium channel HERG expressed in mammalian cellsMore data for this Ligand-Target Pair
In Depth
Date in BDB:
10/8/2012
Entry Details Article
PubMed
TargetMultidrug and toxin extrusion protein 1(Human)
University of California

Curated by ChEMBL
LigandPNGBDBM50366826(Levaquin | Iquix | Floxacin | DR-3355 | LEVOFLOXAC...)
Affinity DataIC50: 1.79E+4nMAssay Description:Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
9/24/2013
Entry Details Article
PubMed
TargetDNA topoisomerase 2-beta(Human)
Sterling-Winthrop Research Institute

Curated by ChEMBL
LigandPNGBDBM50366826(Levaquin | Iquix | Floxacin | DR-3355 | LEVOFLOXAC...)
Affinity DataIC50: 2.76E+3nMAssay Description:Gyrase inhibitory activity against Escherichia coliMore data for this Ligand-Target Pair
In Depth
Date in BDB:
1/3/2019
Entry Details Article
PubMed
TargetPotassium voltage-gated channel subfamily H member 2(Human)
Takeda Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50366826(Levaquin | Iquix | Floxacin | DR-3355 | LEVOFLOXAC...)
Affinity DataIC50: 9.12E+5nMAssay Description:Inhibitory concentration against potassium channel HERGMore data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2013
Entry Details Article
PubMed
TargetPotassium voltage-gated channel subfamily H member 2(Human)
Takeda Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50366826(Levaquin | Iquix | Floxacin | DR-3355 | LEVOFLOXAC...)
Affinity DataIC50: 9.12E+5nMAssay Description:Inhibition of human ERG expressed in CHO cells by whole cell patch clamp techniqueMore data for this Ligand-Target Pair
In Depth
Date in BDB:
5/21/2013
Entry Details Article
PubMed
TargetDNA topoisomerase 2-alpha/2-beta(Human)
Procter & Gamble Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50366826(Levaquin | Iquix | Floxacin | DR-3355 | LEVOFLOXAC...)
Affinity DataIC50: 3.59E+4nMAssay Description:Inhibitory activity against quinolone resistant gyrase in Escherichia coliMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2018
Entry Details Article
PubMed
TargetDNA primase(Bacillus anthracis)
University of Michigan

LigandPNGBDBM50366826(Levaquin | Iquix | Floxacin | DR-3355 | LEVOFLOXAC...)
Affinity DataIC50: 7.50E+4nMpH: 8.8Assay Description:The reaction mixture contained DNA (1.25 uM or as specified), NTP (110 uM or as specified), 50 mM NaCl, 150 mM potassium glutamate, buffer [20 mM CAP...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/30/2014
Entry Details Article
PubMed
TargetDNA topoisomerase 2-alpha/2-beta(Human)
Procter & Gamble Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50366826(Levaquin | Iquix | Floxacin | DR-3355 | LEVOFLOXAC...)
Affinity DataIC50: 1.66E+6nMAssay Description:Inhibitory activity against mammalian DNA topoisomerase IIMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2018
Entry Details Article
PubMed
TargetDNA topoisomerase 2-alpha/2-beta(Human)
Procter & Gamble Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50366826(Levaquin | Iquix | Floxacin | DR-3355 | LEVOFLOXAC...)
Affinity DataEC50: >2.80E+5nMAssay Description:Tested for inhibitory activity against Topoisomerase II isolated from HeLa cells by using SDS-K+ precipitation methodMore data for this Ligand-Target Pair
In Depth
Date in BDB:
9/20/2018
Entry Details

TargetBile salt export pump(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM50366826(Levaquin | Iquix | Floxacin | DR-3355 | LEVOFLOXAC...)
Affinity DataIC50: 1.00E+6nMAssay Description:Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/28/2019
Entry Details Article
PubMed
LigandPNGBDBM50366826(Levaquin | Iquix | Floxacin | DR-3355 | LEVOFLOXAC...)
Affinity DataIC50: 1.33E+5nMAssay Description:Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/3/2019
Entry Details Article
PubMed
TargetBile salt export pump(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM50366826(Levaquin | Iquix | Floxacin | DR-3355 | LEVOFLOXAC...)
Affinity DataIC50: 1.33E+5nMAssay Description:Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/3/2019
Entry Details Article
PubMed
LigandPNGBDBM50366826(Levaquin | Iquix | Floxacin | DR-3355 | LEVOFLOXAC...)
Affinity DataIC50: 1.33E+5nMAssay Description:Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/3/2019
Entry Details Article
PubMed
TargetDNA topoisomerase 2-beta(Human)
Sterling-Winthrop Research Institute

Curated by ChEMBL
LigandPNGBDBM50366826(Levaquin | Iquix | Floxacin | DR-3355 | LEVOFLOXAC...)
Affinity DataKi:  2.49E+3nMAssay Description:Inhibition constant against DNA Gyrase isolated from Escherichia coliMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/25/2018
Entry Details Article
PubMed
TargetDNA topoisomerase 2-beta(Human)
Sterling-Winthrop Research Institute

Curated by ChEMBL
LigandPNGBDBM50366826(Levaquin | Iquix | Floxacin | DR-3355 | LEVOFLOXAC...)
Affinity DataKi:  9.96E+4nMAssay Description:Inhibition constant against DNA Gyrase isolated from Micrococcus luteusMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/25/2018
Entry Details Article
PubMed